Focus on Pathways: Therapeutic Inhibition of XPO1- Mediated Nucleocytoplasmic Transport With SINE Technology
Advertisement
Advertisement
Trending on OncLive
1
STX-001 Produces Durable Systemic Responses in PD-1–Resistant Melanoma
2
RP1 Plus Nivolumab Preserves Quality-Adjusted Survival in Advanced Melanoma After Anti–PD-1 Therapy
3
JNJ-87189401 Plus Pasritamig Drives Deep PSA Responses With Favorable Safety in Pretreated mCRPC
4
Afami-Cel Outcomes Are Tied to MAGE-A4 Expression, Tumor Burden in Synovial Sarcoma
5
